INS and type 2 diabetes mellitus: A multicenter post hoc study investigated the effects of tirzepatide (1, 5, 10, and 15 mg) and dulaglude (1.5 mg) versus placebo on markers of β cell function and insulin sensitivity in 360 subjects with type 2 diabetes.